A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian cancer. A phase 3 trial found that relacorilant, when combined with ...

Johanna Joyce, PhD, then took the rostrum and spoke eloquently on the tumor microenvironment, underscoring the immense ...

Elahere is the first drug to improve survival in platinum-resistant ovarian cancer. "Ovarian cancer can be devastating and, when cancer cells stop responding to chemotherapy, patients may feel ...

The drug, relacorilant, in combination with chemotherapy, reduced the risk of cancer progression by 30% in ovarian cancer patients who were resistant to platinum-based chemotherapy treatments ...

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic ...

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...